Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2009 1
2011 1
2012 3
2013 5
2014 3
2015 1
2021 3
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. Byers LA, et al. Among authors: foulks jm. Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22. Clin Cancer Res. 2013. PMID: 23091115 Free PMC article.
AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.
Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS. Sakemura RL, et al. Among authors: foulks jm. Cancer Immunol Res. 2023 Sep 1;11(9):1222-1236. doi: 10.1158/2326-6066.CIR-22-0254. Cancer Immunol Res. 2023. PMID: 37378662 Free PMC article.
Epigenetic drug discovery: targeting DNA methyltransferases.
Foulks JM, Parnell KM, Nix RN, Chau S, Swierczek K, Saunders M, Wright K, Hendrickson TF, Ho KK, McCullar MV, Kanner SB. Foulks JM, et al. J Biomol Screen. 2012 Jan;17(1):2-17. doi: 10.1177/1087057111421212. Epub 2011 Sep 30. J Biomol Screen. 2012. PMID: 21965114 Review.
ASXL1 mutations are associated with a response to alvocidib and 5-azacytidine combination in myelodysplastic neoplasms.
Riabov V, Xu Q, Schmitt N, Streuer A, Ge G, Bolanos L, Wunderlich M, Jann JC, Wein A, Altrock E, Demmerle M, Mukherjee S, Ali AM, Rapp F, Nowak V, Weimer N, Obländer J, Palme I, Göl M, Jawhar A, Darwich A, Wuchter P, Weiss C, Raza A, Foulks JM, Starczynowski DT, Yang FC, Metzgeroth G, Steiner L, Jawhar M, Hofmann WK, Nowak D. Riabov V, et al. Among authors: foulks jm. Haematologica. 2024 May 1;109(5):1426-1438. doi: 10.3324/haematol.2023.282921. Haematologica. 2024. PMID: 37916386 Free PMC article.
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.
Tyagi A, Jaggupilli A, Ly S, Yuan B, El-Dana F, Hegde VL, Anand V, Kumar B, Puppala M, Yin Z, Wong STC, Mollard A, Vankayalapati H, Foulks JM, Warner SL, Daver N, Borthakur G, Battula VL. Tyagi A, et al. Among authors: foulks jm. Leukemia. 2024 Jan;38(1):82-95. doi: 10.1038/s41375-023-02086-6. Epub 2023 Nov 25. Leukemia. 2024. PMID: 38007585
Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors.
Ho KK, Parnell KM, Yuan Y, Xu Y, Kultgen SG, Hamblin S, Hendrickson TF, Luo B, Foulks JM, McCullar MV, Kanner SB. Ho KK, et al. Among authors: foulks jm. Bioorg Med Chem Lett. 2013 Jan 15;23(2):569-73. doi: 10.1016/j.bmcl.2012.11.013. Epub 2012 Nov 16. Bioorg Med Chem Lett. 2013. PMID: 23232060
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.
Chan TY, Egbert CM, Maxson JE, Siddiqui A, Larsen LJ, Kohler K, Balasooriya ER, Pennington KL, Tsang TM, Frey M, Soderblom EJ, Geng H, Müschen M, Forostyan TV, Free S, Mercenne G, Banks CJ, Valdoz J, Whatcott CJ, Foulks JM, Bearss DJ, O'Hare T, Huang DCS, Christensen KA, Moody J, Warner SL, Tyner JW, Andersen JL. Chan TY, et al. Among authors: foulks jm. Nat Commun. 2021 Sep 9;12(1):5337. doi: 10.1038/s41467-021-25622-3. Nat Commun. 2021. PMID: 34504101 Free PMC article.
18 results